Adivo Overview
- Year Founded
-
2018
- Status
-
Acquired/Merged
- Employees
-
30
- Latest Deal Type
-
M&A
Adivo General Information
Description
Developer of species-specific therapeutic antibodies designed for companion animals. The company's technology utilizes proprietary phage display antibody libraries and de-novo identification processes to create therapeutic antibodies, oncology drug candidates, inflammatory disease treatments, canine antibody libraries, and feline antibody libraries, providing the veterinary medicine market with targeted treatment options for pets with serious diseases.
Contact Information
Website
www.adivo.vetCorporate Office
- Zeppelinstraße 4
- 82178 Puchheim
- Germany
Corporate Office
- Zeppelinstraße 4
- 82178 Puchheim
- Germany
Adivo Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 07-Jun-2023 | Completed | Generating Revenue | |||
| 4. Grant | 06-Oct-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Oct-2020 | Completed | Generating Revenue | |||
| 2. Grant | 30-Apr-2020 | $54.3K | $2.09M | Completed | Generating Revenue | |
| 1. Seed Round | 19-Jul-2018 | $2.09M | $2.09M | Completed | Startup |
Adivo Comparisons
Industry
Financing
Details
Adivo Competitors (10)
One of Adivo’s 10 competitors is SAb Biotherapeutics, a Formerly VC-backed company based in Miami Beach, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SAb Biotherapeutics | Formerly VC-backed | Miami Beach, FL | ||||
| GeoVax Labs | Corporation | Smyrna, GA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ |
Adivo Patents
Adivo Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20250011431-A1 | Anti-canine pd-l1 antibodies | Pending | 27-Mar-2023 | ||
| WO-2024200425-A1 | Anti-canine pd-l1 antibodies | Inactive | 27-Mar-2023 | ||
| US-20250154688-A1 | Feline antibody library | Pending | 18-Feb-2022 | ||
| WO-2023156625-A1 | Feline antibody library | Inactive | 18-Feb-2022 | ||
| CA-3167437-A1 | Modified fc regions | Pending | 19-Feb-2020 | C07K16/00 |
Adivo Signals
Adivo Former Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| European Innovation Council | Accelerator/Incubator | |||
| High-Tech Gründerfonds | Venture Capital | Minority | ||
| Horizon 2020 | Government | |||
| MorphoSys | Corporation | Minority | ||
| OCCIDENT () | Family Office | Minority |
Adivo FAQs
-
When was Adivo founded?
Adivo was founded in 2018.
-
Where is Adivo headquartered?
Adivo is headquartered in Puchheim, Germany.
-
What is the size of Adivo?
Adivo has 30 total employees.
-
What industry is Adivo in?
Adivo’s primary industry is Drug Discovery.
-
Is Adivo a private or public company?
Adivo is a Private company.
-
What is Adivo’s current revenue?
The current revenue for Adivo is .
-
How much funding has Adivo raised over time?
Adivo has raised $2.09M.
-
Who are Adivo’s investors?
European Innovation Council, High-Tech Gründerfonds, Horizon 2020, MorphoSys, and OCCIDENT () have invested in Adivo.
-
Who are Adivo’s competitors?
SAb Biotherapeutics, GeoVax Labs, Bristol-Myers Squibb, Gilead, and Merck & Co. are some of the 10 competitors of Adivo.
-
When was Adivo acquired?
Adivo was acquired on 07-Jun-2023.
-
Who acquired Adivo?
Adivo was acquired by Zoetis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process